In the phase 3 EVER-132-002 trial, patients with HR+HER2− metastatic breast cancer from Asia were treated with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan or chemotherapy, and those receiving sacituzumab govitecan experienced prolonged progression-free survival compared with patients treated with chemotherapy.
- Binghe Xu
- Shusen Wang
- Ming-Shen Dai
